An observational study in Arteriovenous Fistula Maturation Failure in End-stage Renal Disease, sponsored by Ai Peng. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-10.
Sponsored by Ai Peng · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Arteriovenous Fistula with a site in China — 6 open to participants now, 7 under way, none of them phase 3. Arteriovenous Fistula · China.
Among the 20 studies in Arteriovenous Fistula with a site in China, this one is one of 4 that started in 2024, is one of 6 observational ones, and was the 18th registered.
248 studies on the registry are indexed under Arteriovenous Fistula; 44 are open to participants now.
Browse Arteriovenous Fistula studies →6 of the 20 studies in Arteriovenous Fistula with a site in China are open now. Recruiting first, the newest first:
Suzhou Municipal Hospital of Anhui Province · Sites in China
Ages 18–100
DK Medical Technology (Suzhou) Co., Ltd. · Sites in China
Ages 18–80
RenJi Hospital · Sites in China
Ages 18–75
MicroPort NeuroTech Co., Ltd. · Sites in China
Ages 18–80
Acotec Scientific Co., Ltd · Sites in China
Ages 18–85
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 27 Arteriovenous Fistula studies recruiting now, 13 (48%) set no upper age limit and 4 (15%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 4 started in 2024.
This study's planned enrollment of 100 is close to the median of 100 across 71 observational studies indexed under Arteriovenous Fistula.
Median enrollment 184 across the 14 interventional studies, 190 across the 6 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 20 have an industry lead sponsor. The 10 most frequent:
Ai Peng is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Ai Peng has 2 studies filed under Arteriovenous Fistula — fewer than ten, so there is no comparison to draw.
2 of the studies in Arteriovenous Fistula with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07372027Suzhou Municipal Hospital of Anhui ProvinceSingle-Needle Distal Return for Long-Term Arteriovenous Fistula Care | 2026-12-20 |
| NCT06422845DK Medical Technology (Suzhou) Co., Ltd.Peripheral Scoring Drug-coated Balloon in the Treatment of Hemodialysis Arteriovenous Fistula Stenosis | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Arteriovenous Fistula with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to investigate the long-term clinical outcomes and molecular mechanisms of autogenous arteriovenous fistula (AVF) maturation failure in uremic patients. The primary goal is to develop a precision prediction model integrating clinical, imaging, and biomarker data, while secondary objectives focus on identifying key molecular targets regulating AVF maturation.
This observational study aims to investigate the long-term clinical outcomes and molecular mechanisms underlying autogenous arteriovenous fistula (AVF) maturation failure in uremic patients, with the primary goal of developing a precision prediction model integrating clinical, imaging, and biomarker data while also identifying key molecular targets regulating AVF maturation. Conducted as a single-center prospective study at Shanghai Tenth People's Hospital, the research will enroll 300 ESRD patients undergoing first-time AVF creation, collecting comprehensive multi-omics data including clinical parameters (demographics, comorbidities, laboratory tests), ultrasound imaging (vessel diameter, blood flow measurements), and molecular biomarkers (miRNAs, cytokines, vascular remodeling proteins). Using advanced machine learning techniques like Random Forest and XGBoost, the study will construct a predictive model for AVF maturation failure based on KDOQI criteria (blood flow \<600 mL/min, diameter \<6 mm, or depth >6 mm at 6 weeks), while parallel mechanistic investigations will employ WGCNA and Cox regression analyses to elucidate critical molecular pathways such as VEGF/TGF-β signaling and potential therapeutic targets including ALPL and Eph-B4. The study adheres to strict ethical guidelines (Helsinki Declaration, GCP standards) and includes rigorous statistical planning with a sample size calculated to ensure adequate power (300 patients yielding 110 expected events), employing AUC analysis for model discrimination and standard statistical tests for group comparisons. Expected outcomes include the development of a clinically applicable prediction tool (targeting software copyright), 2-3 high-impact SCI publications, and identification of novel therapeutic targets, with the entire project spanning from patient recruitment (2025.07-2026.07) through data analysis and manuscript preparation (2026.11-2027.01), ultimately aiming to significantly improve AVF management through its innovative combination of multi-omics integration and machine learning approaches.
This study will enroll 300 adult ESRD patients undergoing initial autogenous arteriovenous fistula (AVF) creation at Shanghai Tenth People's Hospital. The population represents typical hemodialysis candidates with end-stage renal failure requiring vascular access. Participants will be recruited consecutively from nephrology and vascular surgery clinics, reflecting real-world clinical practice. The cohort will include patients with varied comorbidities (e.g., diabetes, hypertension) but exclude those with conditions that may confound AVF maturation assessment (prior access surgery, limited life expectancy). All patients will receive standard preoperative evaluation including vascular mapping ultrasound.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is an observational study with no investigational interventions. Standard clinical AVF surgical procedures will be performed per hospital protocols.
Arteriovenous fistula maturation failure rate
Failure to meet KDOQI criteria at 6 weeks post-operation (blood flow \<600 mL/min, venous diameter \<6 mm, OR subcutaneous depth \>6 mm) AND inability to sustain hemodialysis (2 sessions/week)
Time frame: 6 weeks and 6 months post-surgery
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Aug 2025, 10 months after the start.
Of 34 observational studies under Arteriovenous Fistula, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ai Peng